Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2014

Long-Acting Injectable vs Oral Antipsychotics for
Relapse Prevention in Schizophrenia: A MetaAnalysis of Randomized Trials
Taishiro Kishimoto
Northwell Health

A. Robenzadeh
Northwell Health

C. Leucht
S. Leucht
K. Watanabe
See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Medical Molecular Biology Commons, and the Psychiatry Commons
Recommended Citation
Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane J, Correll C. Long-Acting Injectable vs
Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. . 2014 Jan 01; 40(1):Article
1053 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/1053. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.

Authors

Taishiro Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe, M. Mimura, M. Borenstein, John
Kane, and Christoph Correll

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/1053

Schizophrenia Bulletin vol. 40 no. 1 pp. 192–213, 2014
doi:10.1093/schbul/sbs150
Advance Access publication December 17, 2012

Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in
Schizophrenia: A Meta-Analysis of Randomized Trials

Taishiro Kishimoto1,2, Alfred Robenzadeh1, Claudia Leucht3, Stefan Leucht3, Koichiro Watanabe2,4, Masaru Mimura2,
Michael Borenstein5, John M. Kane1,6,7,8, and Christoph U. Correll*,1,6,7,8
The Zucker Hillside Hospital, Psychiatry Research, North Shore – Long Island Jewish Health System, Glen Oaks, NY; 2Keio University
School of Medicine, Neuropsychiatry, Shinjuku-ku, Tokyo, Japan; 3Department of Psychiatry and Psychotherapy, Klinikum rechts der
Isar der Technischen Universität München, München, Germany; 4Kyorin University School of Medicine, Neuropsychiatry, Mitaka,
Tokyo, Japan; 5Biostat, Inc, Englewood, NJ; 6Hofstra North Shore LIJ School of Medicine, Department of Psychiatry and Molecular
Medicine, Hempstead, NY; 7Albert Einstein College of Medicine, Deparment of Psychiatry and Behavioral Sciences, Bronx, NY;
8
The Feinstein Institute for Medical Research, Manhasset, NY
1

*To whom correspondence should be addressed; Division of Psychiatry Research, the Zucker Hillside Hospital, 75-59 263rd Street, Glen
Oaks, NY 11004, US; tel: (718) 470-4812, fax: (718) 343-1659, e-mail: ccorrell@lij.edu
Results from this study were presented at the Schizophrenia International Research Society 3rd biennial meeting, April 14–18, Florence,
Italy, and the NCDEU 52nd Annual meeting, May 29-June 1, 2012 Arizona, USA.

Background: While long-acting injectable antipsychotics
(LAIs) are hoped to reduce high relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged
the benefits of LAIs over oral antipsychotics (OAPs).
Methods: Systematic review/meta-analysis of RCTs that
lasted ≥6 months comparing LAIs and OAPs. Primary
outcome was study-defined relapse at the longest time
point; secondary outcomes included relapse at 3, 6, 12, 18,
and 24 months, all-cause discontinuation, discontinuation
due to adverse events, drug inefficacy (ie, relapse + discontinuation due to inefficacy), hospitalization, and nonadherence. Results: Across 21 RCTs (n = 5176), LAIs were
similar to OAPs for relapse prevention at the longest time
point (studies = 21, n = 4950, relative risk [RR] = 0.93,
95% confidence interval [CI]: 0.80–1.08, P = .35). The
finding was confirmed restricting the analysis to outpatient studies lasting ≥1 year (studies = 12, RR = 0.93, 95%
CI:0.71–1.07, P = .31). However, studies using first-generation antipsychotic (FGA)-LAIs (studies = 10, RR = 0.82,
95% CI:0.69–0.97, P = .02) and those published ≤1991
(consisting exclusively of all 8 fluphenazine-LAI studies;
RR = 0.79, 95% CI: 0.65–0.96, P = 0.02) were superior to
OAPs regarding the primary outcome. Pooled LAIs also
did not separate from OAPs regarding any secondary outcomes. Again, studies using FGA-LAIs and those published
≤1991 were associated with LAI superiority over OAPs, eg,
hospitalization and drug inefficacy. Conclusions: In RCTs,
which are less representative of real-world patients than naturalistic studies, pooled LAIs did not reduce relapse compared with OAPs in schizophrenia patients. The exceptions

were FGA-LAIs, mostly consisting of fluphenazine-LAI
studies, which were all conducted through 1991. Because
this finding is vulnerable to a cohort bias, studies comparing FGA-LAI vs second-generation antipsychotics-LAI
and LAI vs OAP RCTs in real-world patients are needed.
Key words: antipsychotics/adherence/depot/long-acting
injection/meta-analysis/relapse/schizophrenia/treatment
discontinuation
Introduction
Because psychopathology and social functioning can
worsen with repeated psychotic episodes in patients with
schizophrenia,1,2 relapse prevention is critical. There is
strong evidence of antipsychotic efficacy for relapse prevention in chronic and first-episode patients,3,4 in that the risk of
relapse is 2–6 times higher without medication.3–6 However,
because nonadherence rates as high as 50% can limit the
efficacy of pharmacotherapy,7,8 the use of long-acting
injectable antipsychotics (LAIs) is an important option.9 In
practice, patients and clinicians are sometimes reluctant to
use LAIs because of stigma, needle pain, time constraints,
side effect concerns, and cost.10 Given these drawbacks to
the use of LAIs, convincing data showing the superiority of
LAI over oral antipsychotics (OAPs) is needed to support
the use of LAIs. The first LAI was introduced in the 1960s.
Since then, at least 5 first-generation antipsychotics (FGAs)LAIs and 3 second-generation antipsychotics (SGA)-LAIs
have become available. Our previous meta-analysis found
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that LAIs were associated with significantly lower relapse
rates than OAPs.11 However, new, large, controlled trials
showed no benefit of LAIs.12–15 We performed a meta-analysis that incorporated the new randomized controlled trials
(RCTs) and also applied broader inclusion criteria. The new
analyses are based on twice as many studies and 3 times as
many patients as compared with the earlier ones.
Method
The meta-analysis was performed following PRISMA
guidelines.16
Search
We conducted a search without language restrictions,
using MEDLINE/PubMed, Cochrane library, PsycINFO
and CINAHL (last search: 06/2012), for RCTs of relapse
prevention or maintenance treatment in schizophrenia
and related disorders lasting ≥6 months. To avoid publication bias, we also included unpublished studies, such as
conference proceedings and clinical trial registries (http://
clinicaltrials.gov/). Search terms included synonyms of (1)
antipsychotic(s); (2) schizophrenia and related disorders,
(3) randomized; and (4) depot, (long-acting) injection(s),
microsphere, decanoate, palmitate, enanthate. The electronic search was supplemented by hand search of reference lists of relevant publications. At least 2 independent
investigators (TK, AR, CL) conducted the literature search.
Inclusion Criteria
We included randomized, head-to-head comparisons
of LAI vs OAP for relapse prevention or maintenance
treatment in schizophrenia. Patients in studies had to be
≥17 years old and have diagnoses of schizophrenia or
schizoaffective disorder according to study diagnoses,
but we included studies having other diagnoses, such as
schizophreniform disorder, if schizophrenia or schizo
affective disorder were the vast majority of the study
population. We included studies with a duration of at
least 24 weeks and that provided information about
relapse-related information, such as study-defined relapse
or rehospitalization. We excluded penfluridol, a onceweekly OAP, considering it neither a LAI nor OAP.
Data Extraction and Outcomes
Data were extracted independently by ≥2 reviewers (TK,
AR, CL, SL, CC). Authors and companies were contacted to provide missing information and unpublished
data. Any disagreements were resolved by discussion.
The primary outcome was study-defined relapse at the
latest point of follow-up. Where possible, the relapse rate
was based on survival curves (which estimate relapse and
take account of dropouts), but in other cases, relapse was
based on the initial number of patients at risk. In those

cases where the paper did not define relapse, we used the
next most-appropriate outcome, typically hospitalization
or psychotic exacerbation (table 1).
Secondary outcomes included relapse at 3, 6, 12, 18,
and 24 months, all-cause discontinuation, discontinuation
due to adverse events, drug inefficacy (defined as relapse
+ discontinuation due to inefficacy; or defined as relapse
when the overlap with discontinuation due to inefficacy
was unclear), hospitalization, and nonadherence (defined
as discontinuation due to nonadherence or study-defined
nonadherence; see online supplementary figure 10).
Data Analysis
We used 2 population sets: (1) the “randomized” or
“intent-to-treat” (IIT) population, where patients who
dropped out due to group assignment are included in the
analysis and (2) the “safety and/or efficacy” population,
which includes only those patients who took ≥1 dose and
received at least one postbaseline assessment. In contrast
to our previous report where the randomized sample was
primary, in this analysis the safety/efficacy population was
primary, while the randomized population was examined
in secondary analyses. All outcomes were dichotomous.
The comparison of LAI vs OAP was performed (1) for
each LAI individually (fluphenazine, risperidone, etc) and
(2) across all pooled LAIs. In each analysis, we computed
the pooled RR with its 95% confidence interval (CI) using
the random-effects model.17 Number-needed-to-treat
(NNT) was calculated where appropriate. With regard to
the heterogeneity, τ², I2, Q, and P-values are reported.
In addition to the primary and secondary outcome analyses, we conducted a series of subgroup/sensitivity analyses.
In order to assess the robustness of the primary outcome, we
repeated the analyses using relapse rates based on the initial
sample size (where available, as well as exclusively), whereas
the primary analysis employed relapse rates based on survival curves (where available, as well as exclusively). While
the primary analysis was based on the full set of studies, we
also conducted analyses on subgroups (identified a priori)
of studies in order to identify potential methodological
biases or different populations. These included subgroups
based on (1) medication group (FGA-LAI vs SGA-LAI),
(2) publication year (older RCTs [published ≤1991] vs newer
RCTs [published ≥2005]); there was a 14 year gap between
the last study published in 1991 and the next study published
in 2005, (3) treatment concealment (double-blind doubledummy vs rater-masked vs open label), (4) in-/outpatient
status (outpatients at baseline or shortly after initiation of
antipsychotic treatment vs mixed patient status [in-/outpatients mixed or inpatients throughout the study]), (5) study
duration (≥1 year vs <1 year), and (6) medication allocation
(same vs different antipsychotics in LAI and OAP arm).
Finally, we also reexamined the results with the same inclusion criteria applied in the previous, more restricted metaanalysis,11 ie, outpatient studies lasting ≥1 year.
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na

88

73d

53

Del Giudice
et al.25 75/USA

Rifkin et al.27
77/USA

Falloon et al.26
78/UK

DBDD 52

DBDD 52

DBDD/ 69
RMc

Definition
of RelapseRelated
Outcome

Mean
Age
(Range)
(y.o.)

NR
Withdrawalb:
termination of (20–65)
the trial due to
significant Sx
that warranted
unblinding the
treatment in
order to inform
future Pt
management
IPs with SCZ who Re-Hpb
NR
responded to oral
(20–50)
FPZ and were
discharged
Relapse: clinical 23.7
Stable OPse on
(17–38)
FPZ depot or oral deterioration
for 4 wks, no more with marked
social
than minor side
effects, cooperative impairment
and compliant
39
SCZ Pts returning Relapse:
to the community reappearance or (17–60)
following Hp of an exacerbation of
acute schizophrenic schizophrenic
episode
features that led
to withdrawal
from the trial,
regardless of
re-Hp
Stable and
cooperative OPs
with SCZ who
are adherent to
medication and
attending the
clinic

Study Duration
Design (wks)
Inclusion Criteria

First-generation antipsychotic LAIs
Fulphenazine depot
Crawford and
31
DBDD 40
Forrest45 74/UK

Study/Country

Table 1. Description of Included Studies

0

0

67

45

0

0

100

29

81% had ≥2
Hps in the
past

Mean # of
Hps in the
past: 1.79

48.8% had
5–10 Hps in
the past

NR

Information
Regarding
Chronicity
(# Hp,
% Hp at Duration of
% Male Baseline illness etc.)

NR
NR

Pimozide

28

FPZ
FPZ
decanoate

23

24

20

28

23

61

61
FPZ
decanoate

27

15

14

27

17

Triflu‑
operazine

FPZ
Enanthate
FPZ

14

FPZ
decanoate

25 mg/2
wksf
(flexible)
8 mg/df
(flexible)

25 mg/2
wks (fixed)
21.7 mg
(5–80 mg)
NR
(0.5–2 ml/
2–wks)
NR
(5–20 mg)

NR (Same
dose as
before the
trial)
10 mg/d
(fixed)

Safety/
Mean Dose
Medication Randomized # Efficacy # (Range)

T. Kishimoto et al

na

105

290

36

263

Study/Country

Hogarty et al.46
79/USA

Schooler et al.43
80/USA

Barnes et al.47
83/UK

Kaneno et al.48
91/Japan
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DBDD 24

DBDD 52

DBDD 52

DBDD 104

Chronic Pts
with SCZ who
need long-term
treatment

59

46

49.5 (NR) 50

29
(18–55)

34.2
(18–55)

Mean
Age
(Range)
(y.o.)

Treatment
NR (NR)i 65
discontinuation
due to worsening of psychiatric Sxb

Relapse:
unequivocal
clinical deterioration of such
magnitude that
Hp appeared
imminent after
all reasonable
attempts to
maintain Pts
with study
medication
failed or suicide
Pts with SCZ dis- Relapse:
charged after acute deterioration
phase treatment
that could not
and being treated managed satin community
isfactory after
adjustment of
dosage within
protocol limits
Relapse:
OPs with SCZ
marked
(PSE) reguexacerbation
larly receiving
of psychotic
depot FPZ for
features requir≥6 months, and
willing to partici- ing increase
medication and
pate the trial
re-Hp
Pts with SCZ
who received
major neuroleptic
treatment during
the Hp and was
discharged

Study Duration
Design (wks)
Inclusion Criteria

Definition
of RelapseRelated
Outcome

NR

0

100/0g

0

Duration of
illness was
≥10 years in
81%

130

133

FPZ
decanoate

HAL

132

127

17

17

107h

19

147

FPZ

107h

50

55

19

143

50

FPZ

FPZ
decanoate

55

FPZ
decanoate

12.6–
50 mg/4
wksf
(−75 mg/4
wks)
3.1–
12.0 mg/df
(−18 mg/d)

NR (same
dose as
before the
trial)
NR (dose
equivalent
before the
trial)

34.2 mg/3
wks (12.5–
100 mg/3
wks)
24.8 mg/d
(2.560 mg/d)

34 mg/2
wks (12.5–
125 mg/2
wks)
9.9 mg/d
(2.5–
40 mg/d)

Safety/
Mean Dose
Medication Randomized # Efficacy # (Range)

≥77.8%
FPZ
have social
decanoate
performance
limitations
Pimozide

100% newly
Hp

88% had ≥1
Hp in the
past

Information
Regarding
Chronicity
(# Hp,
% Hp at Duration of
% Male Baseline illness etc.)
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52

Second-generation antipsychotic-LAIs
Olanzapine-LAI
Kane et al.13 10/
1065l DBDD 24
International

RM

Zuclopenthixol depot
Arango et al.24 06/ 46
Spain

48

Clinically stable
Pts with SCZ
(DSM-IV) defined
as having OP
status for ≥4 wks,
with a BPRS-P ≤4
on the following
items: conceptual
disorganization,
suspiciousness, hallucinatory behavior, and unusual
thought content

Mean
Age
(Range)
(y.o.)

Psychotic exac- 38.9
(18–75)
erbationb: (1)
an increase of
any BPRS-P to
a score of >4,
with an absolute increase
≥2 for the
specific item,
(2) increase of
any BPRS-P to
a score >4, with
an absolute
increase ≥4 on
the positive
subscale, (3)
Hp as the result
of worsening
of positive
psychotic Sx

65

34.0 (NR) 83

0

0

0

21

QUE

599

322

322

20

26

19/16

10/9

599

Zuclopen‑ 26
thixol depot
Zuclopen‑ 20
thixol

14

HAL
decanoate

150 mg/2
wks,
405 mg/4
wks,
300 mg/2
wks (fixed)
14.3 mg/d
(10, 15,
20 mg/d)

233 mg/2
wks (NR)
35 mg/d
(NR)

170 mg/4
wks
(200 mg/4
wksk)
493 mg/d
(500 mg/dk)

Safety/
Mean Dose
Medication Randomized # Efficacy # (Range)

OLA-LAI
Mean
duration
of illness:
13.3 years.
36.9% had
≥2 psychotic
episodes or OLA
exacerbations in last
24 months

NR

Mean
duration
of illness:
16.5 years

Information
Regarding
Chronicity
(# Hp,
% Hp at Duration of
% Male Baseline illness etc.)

42.3 (NR) 80
Pts who were
no longer exacerbation freeb

Definition
of RelapseRelated
Outcome

Hpb
Pts with SCZ
(DSM-IV) who
had a violent
episode in the
previous year, with
a score of at least
3 on the physical
aggression subscale
of the modified
Overt Aggression
Scale

OPs with SCZ or
SzADj (DSM-IV)
who require longterm therapy

Study Duration
Design (wks)
Inclusion Criteria

OL

na

Haloperidol depot
Glick et al.49 05/ 35
USA

Study/Country
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524

Detke et al.50
11/International

OL

53

104

IP/OPs with
SCZ or SzADn
(DSM-IV) who
had acute exacerbation (Hp or
requiring medical
intervention) in the
past 2 months, and
had an additional
acute exacerbation
in the past 2 years,
PANSS-T ≥50,
BMI ≤40

OPs with SCZ
(DSM-IV) who
had no acute Hp in
the 8 wks prior to
visit 1, PANSS-T
< 70, CGI-S ≤ 4 at
visit 1 and 2, but
had ≥2 episode of
clinical worsening
in the past 2 years

Study Duration
Design (wks)
Inclusion Criteria

Risperidone-LAI
Keks et al.51
629m OL
07/International

na

Study/Country

Table 1. Continued

Mean
Age
(Range)
(y.o.)

Significant
35.2
deterioration
(≥18)
b)
: 1) Hp for Sx
exacerbation,
2) need for an
increased level
of care and ≥2
points increase
in CGI-S over
2 wks, 3) selfinjury, suicidal/
homicidal ideation or violent
behavior

40.9
Relapse: (1)
Hp, (2) >25% (18–65)
increase in
PANSS-T,
including
≥25% increase
including ≥10
points increase
(3) ≥1 increase
in CGI-S
CGI-S of ≥4,
(4) deliberate
self-injury or
injury to others,
(5) discontinuation from study
because of
worsening of Sx

Definition
of RelapseRelated
Outcome

57

67

44

0

Mean
duration
of illness:
8.6 years

253

310

OLA

300

247

260

260

RIS-LAI

264

264

40.7 mg/2
wks (25,
50 mg/2
wks)
14.6 mg/d
(5–20 mg/d)

386.6 mg/4
wks (15–
405 mg/4
wks)
12.7 mg/d
(5–20 mg/d)

Safety/
Mean Dose
Medication Randomized # Efficacy # (Range)

OLA LAI
Mean
duration
of illness:
14.7 years.
Mean # of
OLA
psychotic episode in last
24 months:
2.7
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(# Hp,
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% Male Baseline illness etc.)
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OL

41

205

Potapov et al.52
08/Russia

Kamijima et al.38
NCT0024070837
09/Japan

OL

RM

50

Bai et al.23
07/Taiwan

24

52

48

46.4
(18–65)

Relapse:
definition
not given

42.7
(≥20)

34.9
(18–65)

Mean
Age
(Range)
(y.o.)

Definition
of RelapseRelated
Outcome

Relapse: ≥5
increase in
CGI-S and
≥20% in
PANSS-T
compared
with previous
assessment
IP/OPs with SCZ Treatment
discontinuation
(DSM-IV) who
due to worsenare taking RIS
ing of psychiat≤6 mg/d with no
change in dose for ric Sxb
28 days, PANSS-T
≥60–<120

Symptomatically
stable SCZ
(DSM-IV)and have
been on oral RIS
for ≥3 months,
PANSS-T <80,
PANSS conceptual
disorganization,
hallucinatory
behavior, suspiciousness, unusual
thought content
are all <4, CGI-I
screening visit and
baseline were same
Ops with SCZ
(ICD-10) whose
PANSS-T ≥60

Study Duration
Design (wks)
Inclusion Criteria

na

Study/Country
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62

58

50

28

0

100o

Mean
duration
of illness:
14.9 years

NR

153

52

RIS

21

OLA

RIS LAI

20

25

RIS LAI

RIS

25

51

147

20

20

25

23p

32.3 mg/2
wks (25,
37.5,
50 mg/2
wks)
3.4 mg/d
(2–6 mg/d)

15.9 mg/d
(NR)

41.7 mg/2
wks (NR)

Equivalent
to oral
5.0 mg/d
(25, 37.5,
50 mg/2
wks)q
4.0 mg/d
(Same dose
as before
the trial)

Safety/
Mean Dose
Medication Randomized # Efficacy # (Range)

Mean
RIS LAI
duration of
Hop stay:
127.9 months

Information
Regarding
Chronicity
(# Hp,
% Hp at Duration of
% Male Baseline illness etc.)

T. Kishimoto et al

710r OL

Gaebel et al.53
10, de Arce
Cordon et al. 12/
International

104

Symptomatically
stable IP/OPs with
SCZ or SzADs
(DSM-IV) using
stable dose of RIS
≤ 6 mg/d, OLA ≤
20 mg/d, or FGA
≤ 10 mg/d HAL
equivalent for ≥4
weeks and living in
the same residence
for ≥30 days, who
were candidates
for switching Tx.

Study Duration
Design (wks)
Inclusion Criteria

na

Study/Country

Table 1. Continued

Mean
Age
(Range)
(y.o.)

41.6
Relapse: (1)
psychiatric Hp, (≥18)
(2) increase in
level of care
and ≥25%
PANSS-T
increase, including ≥10 points
increase, (3)
deliberate selfinjury, (4) clinically significant
suicidal/homicidal ideation,
(5) violent
behavior resulting in significant injury to
another person
or property, (6)
significant clinical deterioration defined as
a CGI-C ≥6,
(7) exceeding
registered drug
dose

Definition
of RelapseRelated
Outcome
58

NR

Mean
duration
of illness:
10.0 years.
Mean # of
Hps in the
past: 5.3

Information
Regarding
Chronicity
(# Hp,
% Hp at Duration of
% Male Baseline illness etc.)
355

401r

RIS LAI

QUE, ARI

33.6 mg/2
wks (up
to 50 mg/2
wks)
382/371 r) QUE:
413.4 mg/d
(up to
750 mg/d),
ARI:
15.1 mg/d
(10–
30 mg/d)

329/327

Safety/
Mean Dose
Medication Randomized # Efficacy # (Range)
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199

200

na

Macfadden et al.14 355
10/International

Study/Country
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RM

104

Pts with SCZ
(DSM-IV) who
experienced at
least 2 psychotic
relapses in the past
2 years, and have
been stabilized for
≥2 months

Study Duration
Design (wks)
Inclusion Criteria

Mean
Age
(Range)
(y.o.)

37.9
Relapse:
determined by (>18)
masked monitoring board;
(1) worsening
of psychiatric Sx (Hp
or significant
increases in
level of psychiatric care),
(2) an increase
of ≥25%
PANSS-T,
including ≥10
points increase
from baseline,
and CGI-C ≥6
with CGI-S of
≥4, (3) deliberate self-injury,
clinically
significant suicidal/homicidal
ideation, or
violent behavior, (4) drug
discontinuation
or addition
of another
AP for >1 wk
because of lack
of efficacy, (6)
increase in dosage beyond the
recommended
dosage

Definition
of RelapseRelated
Outcome
60

0

RIS LAI

ARI

—

176

179

176/172

179/177

19.9 mg/d
(10–
30 mg/d)

41.8 mg/2
wks (25–
50 mg/2
wks)

Safety/
Mean Dose
Medication Randomized # Efficacy # (Range)

Mean
duration
of illness:
9.9 years

Information
Regarding
Chronicity
(# Hp,
% Hp at Duration of
% Male Baseline illness etc.)

T. Kishimoto et al

RM

RM

Rosenheck et al.12 382
11/USA

Schooler et al.15
11/USA

305

OL

85

NCT0024625944
11/Canada

74–130v

104

104

Pts with SCZ or
SzAD who are
at risk of Hp as
evidenced by current psychiatric Hp,
Hp in the previous
2 years, or increased
use of mental
health services to
prevent relapse
OPs with SCZ or
SzAD (32%) who
had exacerbation
within 12 months,
CGI ≥ 4, in community ≥4 wks,
≥1 month since
the most recent
exacerbation

IPs or OPs with
SCZ, SzAD or
schizophreniform
dsordert (DSM-IV)
with early onset
(≤3 years),
PANSS-T ≥60 and
≤120, currently
on monotherapy
atypical AP below
RIS = 6, OLA = 20,
QUE = 800 mg/d or
treatment naïve. Pts
stable within 18 wks
entered the maintenance phase

Study Duration
Design (wks)
Inclusion Criteria

na

Study/Country
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38.2
Relapse:
(18–65)
determined
by masked
committee; Hp
for psychosis,
increases in level
of care required
to avoid Hp,
substantial clinical deterioration
measured by
BPRS psychosis
cluster, deliberate self-injury or
violent behavior

71

91

Hpb
51.0
(≥18)

84

Mean
Age
(Range)
(y.o.)

22.7
Relapse: (1)
(18–30)
psychiatric
Hp; (2) psychiatric care
increase and
25% increase
in PANSS-T,
including ≥10
points increase;
(3) self-injury,
suicidal, homicidal ideation,
violence; and
(4) CGI-C ≥6

Definition
of RelapseRelated
Outcome

NRw

40

NR

Mean
duration
of illness:
15.9 years.
Mean # of
Hps in the
past: 11.0

Mean
duration
of illness:
23.4 years

Mean
duration
of illness:
2.1 years

Information
Regarding
Chronicity
(# Hp,
% Hp at Duration of
% Male Baseline illness etc.)

35/31 g)

Oral SGA 41
except CLO

150

Oral SGA

152

146

182

Any OAP
192
except CLO

RIS
153
microsphere

187

190

RIS LAI

42/32g

44

RIS LAI

NR
(flexible)

33.6 mg/2
wks (12.5–
75 mg/2
wks)

40.9 mg/1.5
wks
(25,37.5,
50 mg/2
wks)
NR
(flexible)

NR (25–
50 mg/2
wks)u
NR
(flexible
dose)

Safety/
Mean Dose
Medication Randomized # Efficacy # (Range)
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Notes: AP, antipsychotics, BMI, body mass index; BPRS-P, brief psychiatric rating scale positive item; CGI-C, clinical global impression change score; CGI-S, clinical global
impression severity score; CLO, clozapine; DBDD, double-blind double-dummy; Dx, diagnosis; FPZ, fulphenazine; HAL, haloperidol; Hp, hospitalization; IP, inpatient; LAI,
long acting injection; NR, not reported; OAP, oral antipsychotic; OL, open label; OLA, Olanzapine; OP, outpatient; PANSS, positive and negative symptom scale total score;
PSE, present state examination; Pt, patient; QUE, quetiapine; RIS, risperidone; RM, rater masked; SCZ, schizophrenia; SGA, second-generation antipsychotics; Sx, symptom;
SzAD, schizoaffective disorder; Tx, therapy.
a
Original study sample size.
b
Study-defined relapse-related outcomes used in place of relapse.
c
Raters were masked for 3 arms, but DBDD were applied to 2 arms.
d
Pts allocated to placebo arm are not included in the analysis.
e
100% Schizophrenia by clinical diagnosis but included 15% nonschizophrenia when assessed by research psychiatrists.
f
Most common dosing.
g
100% during intensive treatment phase, 0% in maintenance phase.
h
Pts entered maintenance phase are used in the safety/efficacy population analysis.
i
Age range was not reported but 90% of the Pts were between 30–59 years old.
j
Rate not reported.
k
Clinicians were instructed to target this dose.
l
Very low dose (OLA-LAI 45 mg/4 wks) group is not included in the analysis.
m
Pts allocated to RIS LAI 75 mg/2 wks were excluded due to protocol change.
n
ScAD = 17.3%.
o
All the patients were required to be hospitalized throughout the trial.
p
Two Pts were discharged due to stable condition and removed from the trial.
q
Depot dose based on prior oral dose.
r
Including exploratory arm (ARI), randomized: n = 45, efficacy: n = 44.
s
ScAD = 17.7%.
t
ScAD = 6.5%, schizophreniform = 3.9%.
u
Started from 25 mg, but was increased by increments of 12.5 mg up to 50 mg corresponding to the symptoms.
v
Full study period ranged between 17–30 months depending on enrollment date.
w
OP study including some Pts that were briefly hospitalized initially.
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In post-hoc analyses, we compared the chlorpromazine
(CPZ) equivalents between the LAI arm and OAP arm
in the following study groups in order to identify potential confounders: all studies, using the same or different
antipsychotic in the LAI and OAP groups, FGA- or
SGA-LAI studies, and older or newer studies. We also
compared mean CPZ equivalents within each of the OAP
and LAI arms between FGA- vs SGA-LAI studies and
between older vs newer studies. Antipsychotic doses were
converted to CPZ equivalents using published guidelines.18–20 For LAIs, we used the manufacturers’ recommended equivalent for the depot to oral conversion for the
same drug and then converted to oral CPZ equivalents.
Data were entered into a funnel graph (trial effect
against trial size) to investigate the likelihood of overt
publication bias.21 Data were double entered into Review
Manager 5.1.4 (Cochrane Collaboration, http://ims.
cochrane.org/revman).
Results
Search and Study Characteristic
We identified 21 RCTs with 5176 participants (see online
supplementary figure 1). One study22 was excluded
because it did not quantify the number of patients at risk
but reported only completed cases.
The number of patients per study ranged from 31–921
(median: 105), and mean study duration was 66.4 ± 32.2
(range: 24–130) weeks; duration: <1year: studies = 4,
≥1year: studies = 17). Nine studies had a double-blind,
double-dummy design, 5 were rater-masked, and 7 were
open. There were 10 FGA-LAI and 11 SGA-LAI studies. The number of studies with each individual LAI were
fluphenazine = 8, haloperidol = 1, zuclopenthixol = 1, risperidone = 9, olanzapine = 2. The number of the studies
with each OAP were fluphenazine = 4, pimozide = 2, haloperidol = 1, trifluoperazine = 1, zuclopenthixol = 1, olanza
pine = 4, quetiaapine = 2, risperidone = 2, aripiprazole = 2,
and previous medication/physicians’ choice = 3. Eleven
studies (52.4%) used different antipsychotics in the 2 arms.
Thirteen studies (61.9%) included only outpatients, 2 (9.5%)
included inpatients at baseline who were discharged shortly
after study initiation,12,15 1 (4.8%) required patients to be
hospitalized throughout the trial,23 while 5 (23.8%) provided
insufficient information. Relapse definitions varied. In 9
studies (42.9%), relapse was not defined. In 3 of these, we
used hospitalization rate as relapse12,24,25; in the remaining 6,
we utilized study-defined symptomatic worsening (table 1).
Relapse Rate at the Longest Study Time Point
Analyzing individual LAIs, fluphenazine-LAI showed
significant superiority over OAPs (studies = 8, n = 826,
RR = 0.79, 95% CI: 0.65–0.96, P = .02, I2 = 23%,
NNT = 13), while the other LAIs were not significantly
superior to OAPs (pooled RRs for each LAI ranged

from 0.99–1.28). When pooled together, the risk for LAIs
was similar to the risk for OAPs (studies = 21, n = 4950,
RR = 0.93, 95% CI: 0.80–1.08, P = .35). The risk ratio varied across studies (τ2 = 0.05, I2 = 58%, Q = 47.31, df = 20,
P = .0005) (figure 1).
Relapse Rate at Specific Time Points
Comparing relapse rates at different time points (3, 6, 12,
18, and 24 months), pooled LAIs did not separate from
OAPs (see online supplementary figures 2, 3, 4, 5, 6).
A single study of fluphenazine depot yielded trend-level
superiority at 18 months (study = 1, n = 105, RR = 0.66,
95% CI: 0.44–0.99, P = .05) and significant superiority
at 24 months (study = 1, n = 105, RR = 0.56, 95% CI:
0.38–0.80, P = .002); 2 studies of olanzapine-LAI yielded
trend-level inferiority at 6 months (studies = 2, n = 1445,
RR = 1.27, 95% CI: 0.97–1.66, P = .09).
All-Cause Discontinuation
Neither individual LAI nor pooled LAIs separated from
OAPs regarding all-cause discontinuation (pooled LAIs:
studies = 21, n = 4882, RR = 1.00, 95% CI: 0.89–1.13,
P = .99) (figure 2).
Discontinuation Due to Adverse Events
Neither individual nor pooled LAIs separated from
OAPs regarding discontinuation due to adverse events in
the safety/efficacy (pooled LAIs: studies = 19, n = 4662,
RR = 1.10, 95% CI: 0.74–1.64, P = .65) (see online supplementary figure 7).
Drug Inefficacy
Among individual LAIs, only fluphenazine was superior
to OAPs regarding drug inefficacy defined as relapse +
discontinuation due to inefficacy (studies = 8, n = 826,
RR = 0.78, 95% CI: 0.66–0.91, P = .002) in the safety/efficacy population. Conversely, olanzapine-LAI was inferior to OAP on this measure (n = 1445, RR = 1.52, 95%
CI: 1.12–2.07, P = .007), but this was based on only 2
studies. Pooled LAIs did not separate from OAPs regarding drug inefficacy (see online supplementary figure 8).
Hospitalization
Among individual LAIs, only fluphenazine-LAI was
superior to OAPs in preventing hospitalization (studies = 4, n = 197, RR = 0.82, 95% CI: 0.67–0.99, P = .04).
Pooled LAIs showed trend-level superiority over OAPs
(studies = 10, RR = 0.89, 95% CI: 0.78–1.02, P = .09) (see
online supplementary figure 9).
Nonadherence
Only 2 studies utilized pill counts or urine concentration.26,27 One zuclopenthixol study yielded trend-level
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LAI
OAP
Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
1.7.1 Relapse (estimated rate preferred, longest time point) - Fluphenazine depot
Barnes 1983
Crawford 1974
Del Guidice 1975
Falloon 1978
Hogarty 1979
Kaneno 1991
Rifkin 1977
Schooler 1980
Subtotal (95% CI)

3
2
21
8
22
8
2
54

19
14
27
20
55
127
23
107
392

3
6
59
5
36
9
3
61

17
15
61
24
50
132
28
107
434

0.9%
1.0%
9.6%
2.0%
6.8%
2.1%
0.7%
8.8%
32.0%

Risk Ratio
M-H, Random, 95% CI

0.89 [0.21, 3.85]
0.36 [0.09, 1.48]
0.80 [0.65, 0.99]
1.92 [0.74, 4.95]
0.56 [0.38, 0.80]
0.92 [0.37, 2.32]
0.81 [0.15, 4.45]
0.89 [0.69, 1.14]
0.79 [0.65, 0.96]

Total events
120
182
Heterogeneity: Tau² = 0.02; Chi² = 9.06, df = 7 (P = 0.25); I² = 23%
Test for overall effect: Z = 2.33 (P = 0.02)
1.7.2 Relapse (estimated rate preferred, longest time point) - Haloperidol depot
Glick 2005
Subtotal (95% CI)

5

9
9

Total events
5
Heterogeneity: Not applicable
Test for overall effect: Z = 0.03 (P = 0.97)

9

16
16

3.1%
3.1%

0.99 [0.48, 2.04]
0.99 [0.48, 2.04]

9

1.7.3 Relapse (estimated rate preferred, longest time point) - Olanzapine LAI
Detke 2011
Kane 2010
Subtotal (95% CI)

102
58

264
599
863

104
23

260
322
582

9.5%
5.5%
14.9%

0.97 [0.78, 1.19]
1.36 [0.85, 2.16]
1.08 [0.78, 1.47]

Total events
160
127
Heterogeneity: Tau² = 0.03; Chi² = 1.77, df = 1 (P = 0.18); I² = 44%
Test for overall effect: Z = 0.45 (P = 0.65)
1.7.4 Relapse (estimated rate preferred, longest time point) - Risperidone LAI
Bai 2007
Gaebel 2010
Kamijima 2009
Keks 2007
MacFadden 2010
NCT00246259
Potapov 2008
Rosenheck 2011
Schooler 2011
Subtotal (95% CI)

2
65
18
25
90
11
4
86
75

23
327
147
247
177
32
20
187
146
1306

0
136
5
27
82
5
8
90
62

25
371
51
300
172
31
20
182
150
1302

0.2%
8.7%
2.1%
4.8%
9.4%
2.1%
1.8%
9.4%
8.9%
47.4%

5.42 [0.27, 107.20]
0.54 [0.42, 0.70]
1.25 [0.49, 3.19]
1.12 [0.67, 1.89]
1.07 [0.86, 1.32]
2.13 [0.84, 5.43]
0.50 [0.18, 1.40]
0.93 [0.75, 1.15]
1.24 [0.97, 1.59]
0.98 [0.75, 1.28]

Total events
376
415
Heterogeneity: Tau² = 0.09; Chi² = 30.92, df = 8 (P = 0.0001); I² = 74%
Test for overall effect: Z = 0.15 (P = 0.88)
1.7.5 Relapse (estimated rate preferred, longest time point) - Zuclopenthixol depot
Arango 2006
Subtotal (95% CI)

10

26
26

Total events
10
Heterogeneity: Not applicable
Test for overall effect: Z = 0.59 (P = 0.56)

6

20
20

2.5%
2.5%

1.28 [0.56, 2.93]
1.28 [0.56, 2.93]

6

Total (95% CI)

2596
2354 100.0%
0.93 [0.80, 1.08]
Total events
671
739
Heterogeneity: Tau² = 0.05; Chi² = 47.31, df = 20 (P = 0.0005); I² = 58%
0.05 0.2
1
5
20
Test for overall effect: Z = 0.93 (P = 0.35)
Favours LAI Favours OAP
Test for subgroup differences: Chi² = 3.99, df = 4 (P = 0.41), I² = 0%

Fig. 1. Relapse rate-estimated rate preferred, longest time point (safety/efficacy population).
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LAI
OAP
Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
1.1.1 All-cause discontinuation - Fluphenazine depot
0.89 [0.31, 2.56]
1.4%
17
5
19
Barnes 1983
5
0.36 [0.09, 1.48]
0.8%
15
6
14
Crawford 1974
2
1.06 [0.52, 2.16]
2.7%
61
17
27
Del Guidice 1975
8
1.20 [0.55, 2.62]
2.3%
24
8
20
Falloon 1978
8
0.84 [0.42, 1.68]
2.8%
16 132
Kaneno 1991
13 127
2.26 [1.08, 4.71]
2.6%
28
7
23
Rifkin 1977
13
0.88 [0.70, 1.11]
9.2%
66 107
Schooler 1980
58 107
1.00 [0.75, 1.34]
384 21.9%
337
Subtotal (95% CI)

Risk Ratio
M-H, Random, 95% CI

125
Total events
107
Heterogeneity: Tau² = 0.04; Chi² = 8.18, df = 6 (P = 0.22); I² = 27%
Test for overall effect: Z = 0.03 (P = 0.98)
1.1.2 All-cause discontinuation - Haloperidol depot
19
12
10
Glick 2005
5
19
10
Subtotal (95% CI)
Total events
5
Heterogeneity: Not applicable
Test for overall effect: Z = 0.65 (P = 0.52)

2.7%
2.7%

0.79 [0.39, 1.61]
0.79 [0.39, 1.61]

10.7%
8.7%
19.4%

1.05 [0.90, 1.23]
1.51 [1.18, 1.94]
1.24 [0.86, 1.81]

12

1.1.3 All-cause discontinuation - Olanzapine LAI
Detke 2011
Kane 2010
Subtotal (95% CI)

145
180

264
599
863

136
64

260
322
582

200
Total events
325
Heterogeneity: Tau² = 0.06; Chi² = 6.28, df = 1 (P = 0.01); I² = 84%
Test for overall effect: Z = 1.15 (P = 0.25)
1.1.4 All-cause discontinuation - Risperidone LAI
Bai 2007
Gaebel 2010
Kamijima 2009
Keks 2007
MacFadden 2010
NCT00246259
Potapov 2008
Rosenheck 2011
Schooler 2011
Subtotal (95% CI)

3
178
37
87
53
16
8
68
74

23
329
147
247
179
42
20
187
146
1320

0
253
12
114
50
20
9
55
55

25
382
51
300
176
35
20
182
150
1321

0.2%
11.4%
3.8%
9.3%
7.2%
4.7%
2.6%
7.8%
8.4%
55.5%

7.58 [0.41, 139.32]
0.82 [0.72, 0.92]
1.07 [0.61, 1.89]
0.93 [0.74, 1.16]
1.04 [0.75, 1.44]
0.67 [0.41, 1.08]
0.89 [0.43, 1.83]
1.20 [0.90, 1.61]
1.38 [1.06, 1.80]
1.00 [0.83, 1.19]

568
Total events
524
Heterogeneity: Tau² = 0.04; Chi² = 21.07, df = 8 (P = 0.007); I² = 62%
Test for overall effect: Z = 0.02 (P = 0.98)
1.1.5 All-cause discontinuation - Zuclopenthixol depot
Arango 2006
Subtotal (95% CI)

2

26
26

Total events
2
Heterogeneity: Not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI)

2556

3

0.6%
0.6%

0.51 [0.09, 2.78]
0.51 [0.09, 2.78]

2326 100.0%

1.03 [0.90, 1.18]

20
20

3

908
Total events
963
Heterogeneity: Tau² = 0.04; Chi² = 44.31, df = 19 (P = 0.0009); I² = 57%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi² = 2.29, df = 4 (P = 0.68), I² = 0%

0.05 0.2
1
5
20
Favours LAI Favours OAP

Fig. 2. All-cause discontinuation (safety/efficacy population).
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superiority regarding adherence (study = 1, n = 46,
RR = 0.26, 95% CI: 0.06–1.14, P = .07). Pooled LAIs
did not separate from OAPs (studies = 10, n = 2018,
RR = 0.77, 95% CI: 0.49–1.22, P = .22; see online supplementary figure 10).
Sensitivity and Subgroup Analyses: Primary Outcome
Pooled LAIs did not separate from OAPs whether raw
relapse rates were used preferentially over estimated
relapse rates (P = .49), or whether only estimated rates
(P = .25) or raw rates (P = .48) were used.
Nonsuperiority of LAIs over OAP remained in all clinically relevant subpopulations and treatment groups, ie,
treatment concealment (double-blind, double-dummy vs
rater-masked vs open label), in-/outpatient status, study
duration (≥1 year, or <1 year), using the same vs different
medication in the LAI and OAP arm (table 2). When we
repeated the analyses with more stringent inclusion criteria, which we had applied in our previous meta-analysis,11
ie, outpatient study lasting ≥1 year, pooled LAIs again
did not separate from OAPs (studies = 12, n = 2162,
RR = 0.93, 95% CI:0.71–1.07; table 2).
Analyzing FGA-LAIs and SGA-LAIs separately,
FGA-LAIs were significantly superior to OAPs in preventing relapse (studies = 10, n = 897, RR = 0.82,
95% CI: 0.69–0.97, P = .02, NNT = 15). However,
SGA-LAIs did not separate from OAPs (studies = 11,
n = 4053, RR = 1.00, 95% CI: 0.81–1.23, P = 1.0; figure 3). Nevertheless, effect sizes for FGA-LAIs and SGALAIs were not significantly different from each other
(P = 0.14). Furthermore, the superiority of FGA-LAIs,
was moderated by publication year. In RCTs published
until 1991 (studies = 8, n = 826, RR = 0.79, 95% CI: 0.65–
0.96, P = .02, I2 = 23, NNT = 13), consisting exclusively
of all fluphenazine LAIs, LAIs were superior to OAPs.
However, this was not the case in the newer RCTs published since 2005 (studies = 13, n = 4124, RR = 1.01, 95%
CI: 0.83–1.22, P = .94), which included only 2/10 FGALAI studies; figure 3).
Subgroup Analyses: Secondary Outcome
Limiting the sensitivity analyses to variables that showed
a significant effect on the treatment comparison, superiority of FGA-LAIs over OAPs but not of SGA-LAIs
over OAPs was also apparent regarding some secondary outcomes, such as drug inefficacy or hospitalization.
However, again, the results were moderated by publication year (table 2).
CPZ Dose Within and Across Studies
Only 13 of the 21 studies (61.9%) reported mean dose
levels in both treatment arms. Converting antipsychotic
doses to CPZ equivalents, we found no significant differences between LAI and OAP CPZ equivalents across
206

all studies (studies = 13, P = .11), within studies using
the same antipsychotics in the LAI and OAP arms (studies = 8, P = .95), FGA-LAI studies (studies = 5, P = .63),
SGA-LAI studies (studies = 8, P = .15), and older studies (studies = 3, P = 1.0). However, there was a trendlevel difference for higher CPZ equivalents in OAP arms
compared with LAI arms within studies using different
antipsychotics (studies = 5, P = .06) and in newer studies
(studies = 10, P = .06).
Comparing FGA- and SGA-LAI studies, there was a
trend-level difference for higher CPZ equivalent doses in
FGA-LAI studies in both LAI arms (15 treatment arms,
P = .08) and OAP arms (14 treatment arms, P = .08).
Moreover comparing older vs newer studies, CPZ equivalent doses were significantly higher both in the LAI arms
(15 treatment arms, P = .01) and in the OAP arms (14
treatment arms, P = .03) of the older studies.
Randomized Population
Using the randomized population, the results did not
change, except for few minor variations: fluphenazineLAI showed trend level superiority over OAP regarding
relapse at 3 months (P = .06) and at 12 months (P = .08),
hospitalization for pooled LAIs did not reach statistical
significance (P = 0.14), and double-blind double-dummy
study design was associated with trend-level superiority
of LAIs vs OAPs (P = .09).
Publication Bias
The symmetrical funnel-plot did not suggest overt publication bias (see online supplementary figure 11).
Discussion
To our knowledge, this is the largest meta-analysis comparing LAI vs OAP efficacy for relapse prevention in
schizophrenia. Compared with our prior meta-analysis,11 we broadened the inclusion criteria by incorporating studies that enrolled inpatients and outpatients, and
also by including studies lasting 6 months to <1 year.
However, at the same time, we also examined the result
within the studies meeting our previous inclusion criteria
(outpatient study, lasting ≥1 year).
We found that pooled LAIs were not superior to OAPs
in all of the examined relapse-related outcomes. The
only exception was fluphenazine-LAI, which showed
significant superiority over OAPs in several relapserelated outcomes. This lack of superiority of LAIs is in
contrast to our previous meta-analysis,11 which showed
significant superiority of LAIs over OAPs in schizophrenia with a NNT = 10. However, this difference
is not due to the use of broadened inclusion criteria
for analyzed studies, as results were similar when the
analyses were limited to the outpatient studies lasting
≥1 year. Rather, the nonsuperiority of LAIs vs OAPs

4963
3684
4605
897
4053
826
4124
1717
1108
2095
3137
1813
3470
1480
2544
2406
2162
897
4072
826
4143
243
2098
197
2144

10
11
8
13
9
5
7
15
6
15
6
10
11
12
10
11
8
13
5
5
4
6

n

21
12
19

# Trials

0.82
0.93

0.84
0.91

0.78
1.07

0.80
1.07

0.93

0.92
0.94

0.91
1.14

0.95
1.05

0.86
1.07
0.91

0.79
1.01

0.82
1.00

0.95
0.91
0.94

RR

Relative Risk

0.67, 0.99
0.77, 1.12

0.69, 1.01
0.74, 1.12

0.66, 0.91
0.87, 1.33

0.69, 0.93
0.85, 1.36

0.81, 1.07

0.78 1.09
0.71, 1.26

0.77, 1.07
0.82, 1.58

0.83, 1.08
0.61, 1.79

0.68, 1.09
0.93, 1.23
0.64, 1.28

0.65, 0.96
0.83, 1.22

0.69, 0.97
0.81, 1.23

0.81, 1.11
0.77, 1.07
0.78, 1.12

95% CI

0.04
0.43

0.07
0.37

0.002
0.51

0.004
0.55

0.31

0.35
0.70

0.25
0.43

0.41
0.86

0.21
0.34
0.58

0.02
0.94

0.02
0.99

0.49
0.25
0.48

P

0
19

0
29

0
64

0
70

48

47
68

66
0

45
69

45
9
70

23
64

15
70

55
71
51

I2(%)

9
NA

NA
NA

15
NA

17
NA

NA

NA
NA

NA
NA

NA
NA

NA
NA
NA

12
NA

15
NA

NA
NA
NA

NNT

Notes: AP, antipsychotics; FGA, first-generation antipsychotics; LAI, long-acting injection; NA, not applicable; NNT, number needed to treat; OAP, oral antipsychotics; SGA,
second-generation antipsychotics; RCTs, randomized controlled trial. P-values <.05 bolded to indicate statistical significance.

Relapse rate
Relapse rate calculation
   Using preferentially raw over estimated rates
   Using only estimated rates
   Using only raw rates
Medication class
  FGA-LAIs
  SGA-LAIs
Publication year
  Older RCTs ≤1991
  Newer RCTs ≥2005
Treatment concealment
  Double-blind double-dummy
  Rater-masked
  Open label
In-/outpatient status at baseline
  Outpatient status
   Mixed patient status
Study duration
  ≥1 year
  <1 year
Medication allocation
   Same AP in LAI and OAP arm
   Different AP in LAI and OAP arm
Combination of categories
   Outpatient status + ≥1 year
Drug inefficacy
Medication class
  FGA-LAIs
  SGA-LAIs
Publication year
  Older RCTs ≤1991
  Newer RCTs ≥2005
Hospitalization
Medication class
  FGA-LAIs
  SGA-LAIs
Publication year
  Older RCTs ≤1991
  Newer RCTs ≥2005

Variables

Table 2. Subgroup and Sensitivity Analysis in Safety/Efficacy Population
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LAI
OAP
Study or Subgroup Events Total Events Total Weight
2.12.1 FGA-LAIs </=1991
Barnes 1983
Crawford 1974
Del Guidice 1975
Falloon 1978
Hogarty 1979
Kaneno 1991
Rifkin 1977
Schooler 1980
Subtotal (95% CI)

3
2
21
8
22
8
2
54

19
14
27
20
55
127
23
107
392

3
6
59
5
36
9
3
61

17
15
61
24
50
132
28
107
434

Risk Ratio
M-H, Random, 95% CI

0.9%
1.0%
9.6%
2.0%
6.8%
2.1%
0.7%
8.8%
32.0%

Risk Ratio
M-H, Random, 95% CI

0.89 [0.21, 3.85]
0.36 [0.09, 1.48]
0.80 [0.65, 0.99]
1.92 [0.74, 4.95]
0.56 [0.38, 0.80]
0.92 [0.37, 2.32]
0.81 [0.15, 4.45]
0.89 [0.69, 1.14]
0.79 [0.65, 0.96]

120
Total events
182
Heterogeneity: Tau² = 0.02; Chi² = 9.06, df = 7 (P = 0.25); I² = 23%
Test for overall effect: Z = 2.33 (P = 0.02)
2.12.2 FGA-LAIs >/=2005
Arango 2006
Glick 2005
Subtotal (95% CI)

10
5

26
9
35

6
9

20
16
36

2.5%
3.1%
5.6%

1.28 [0.56, 2.93]
0.99 [0.48, 2.04]
1.11 [0.64, 1.91]

15
Total events
15
Heterogeneity: Tau² = 0.00; Chi² = 0.23, df = 1 (P = 0.63); I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
2.12.3 SGA-LAIs >/=2005
Bai 2007
Detke 2011
Gaebel 2010
Kamijima 2009
Kane 2010
Keks 2007
MacFadden 2010
NCT00246259
Potapov 2008
Rosenheck 2011
Schooler 2011
Subtotal (95% CI)

2
102
65
18
58
25
90
11
4
86
75

23
264
327
147
599
247
177
32
20
187
146
2169

0
104
136
5
23
27
82
5
8
90
62

25
260
371
51
322
300
172
31
20
182
150
1884

0.2%
9.5%
8.7%
2.1%
5.5%
4.8%
9.4%
2.1%
1.8%
9.4%
8.9%
62.4%

5.42 [0.27, 107.20]
0.97 [0.78, 1.19]
0.54 [0.42, 0.70]
1.25 [0.49, 3.19]
1.36 [0.85, 2.16]
1.12 [0.67, 1.89]
1.07 [0.86, 1.32]
2.13 [0.84, 5.43]
0.50 [0.18, 1.40]
0.93 [0.75, 1.15]
1.24 [0.97, 1.59]
1.00 [0.81, 1.23]

536
542
Total events
Heterogeneity: Tau² = 0.07; Chi² = 32.93, df = 10 (P = 0.0003); I² = 70%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI)

2596

2354 100.0%

671
739
Total events
Heterogeneity: Tau² = 0.05; Chi² = 47.31, df = 20 (P = 0.0005); I² = 58%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi² = 3.18, df = 2 (P = 0.20), I² = 37.1%

0.93 [0.80, 1.08]
0.05

0.2
1
5
Favours LAI Favours OAP

20

Fig. 3. Subgroup analysis comparing (1) FGA-LAI studies published ≤1991, (2) FGA-LAI studies published ≥2005, (3) SGA-LAI
studies published ≥2005.
When FGA-LAIs (combining the top two groups) and second-generation antipsychotics (SGA)-LAIs (bottom group) were analyzed
separately, FGA-LAIs were significantly superior to OAPs in preventing relapse (Studies = 10, n = 897, RR = 0.82, 95% CI: 0.69–0.97,
P = 0.02, NNT = 15, heterogeneity: τ2 = 0.01, I2 = 15%, Q = 10.62, df = 9, P = 0.30), but SGA-LAIs were not (Studies = 11, n = 4053,
RR = 1.00, 95% CI: 0.81–1.23, P = 0.99, heterogeneity: τ2 = 0.07, I2 = 70%, Q = 32.93, df = 10, P = 0.0003). When older randomized
controlled trials (RCTs) (<1991) (top group) and the remaining newer RCTs (>2005) (combining the bottom two groups) were analyzed
separately, LAIs had lower relapse rates in older RCTs (Studies = 8, n = 826, RR = 0.79, 95% CI: 0.65–0.96, P = 0.02, NNT = 13,
heterogeneity: τ2 = 0.02, I2 = 23%, Q = 9.06, df = 7, P = 0.25), but not in the remaining newer RCTs (Studies = 13, n = 4950, RR = 1.01,
95% CI: 0.83–1.08, P = 0.95, heterogeneity: τ2 = 0.06, I2 = 64%, Q = 33.39, df = 12, P = 0.0008).

in the extended analyses of our study was due to a shift
in the RR toward the null hypothesis rather than due
to increased imprecision indicated by a widening of the
CI. In fact, the CI of our primary result was slightly
narrower than in the prior meta-analysis (RR = 0.93
[95% CI: 0.80–1.08] vs RR= 0 .70 (95% CI: 0.57–0.87]),
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suggesting that the point estimate was, if anything,
somewhat more precise.
On the other hand, we found in subgroup analyses
that FGA-LAIs studies or older RCTs showed significant
superiority of LAIs over OAPs but that this was not the
case in SGA-LAIs studies or newer RCTs. (In a byline,
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we note that the distinction between FGAs and SGAs
is a questionable one.)28 However these findings require
cautionary interpretation. Eight out of 10 FGA-LAI
studies were published by 1991, and all 8 RCTs published
by 1991 employed exclusively fluphenazine-LAI. Hence,
these distinctions were nearly equal, and it is impossible to disentangle the potential reasons for different
effect sizes. Moreover, the subgroup analysis comparing
the effect sizes of FGA-LAIs and SGA-LAIs relative to
OAPs did not yield a significant difference, suggesting
that in this indirect comparison, there was no indication
that FGA-LAIs are superior to SGA-LAIs. That being
said, we consider the following explanations for the differential findings for FGA-LAIs (or older RCTs). One
possibility is publication bias. Because the registration
system of clinical trials has been introduced, companies
are obliged to either publish all studies or make the data
publically available, while in earlier years, studies showing
less advantages for LAIs may not have been published.
Another possibility is changing definitions of relapse.
In order to mitigate potential adverse consequences of
participating in clinical trials, recent studies tended to
utilize lower thresholds for relapse, which can increase
the rate of false positives. From the definitions encountered in these analyses, this tendency was not obvious
(see table 1). However, it is hard to rule out this possibility, as some older studies used vague definitions rather
than quantitative measures, such as predefined changes in
PANSS score. In addition to various definitions, thresholds used to determine relapse can also have a big impact.
For example, hospitalization as threshold is susceptible to
health insurance system variations, social supports, or clinician’s judgment and can differ by geographical regions
or over time. Furthermore, the OAPs used in FGA-LAI
studies published until 1991 were FGAs, while OAPs
used in SGA-LAI studies published since 2005 were
generally SGAs. One can argue that patients allocated
to FGA-OAPs might have a greater chance of relapse,
either due to poorer adherence or differences in neuropharmacologic properties compared with SGA-OAPs.
This could be consistent with our recent meta-analysis
comparing oral SGAs and FGAs, which showed a small
but significant superiority of SGAs in preventing relapse,
but due to limited information, we could not determine
whether nonadherence was a factor.29 We examined this
possibility in the current analyses as well, but we did not
find significant group differences. However, adherence
is rarely assessed directly, and the evaluations involving
these outcomes are very crude, which is a major limitation of the available RCTs. LAIs are thought to be better
via improved adherence, not via intrinsically better efficacy. Therefore, it is unclear whether LAIs were not superior because compliance with OAPs was good enough in
the context of RCTs.
Regarding CPZ equivalent doses, there were some
significant or trend-level differences within and across

studies. CPZ equivalents trended toward being higher in
OAP arms compared with LAI arms within studies using
different antipsychotics, which may have disadvantaged
the LAI arms. However, in the studies that used the same
medications in the LAI and OAP arm and used also similar CPZ equivalent doses in both arms, there was also
no difference in terms of preventing relapse. In SGALAI studies, or newer studies, CPZ equivalent doses in
the OAP arms also trended to be higher than in the LAI
arms. In addition, CPZ equivalent dosages used in FGALAI studies and in older studies were at a trend level
and significantly higher than in SGA-LAI studies and in
newer studies, respectively. These findings are consistent
with a trend toward using lower antipsychotic doses since
the more widespread use of SGAs. Whether or not this
difference is relevant for the superiority of FGA–LAIs
and older studies that used higher doses in both the
LAI and OAP arms than SGA-LAI and newer studies
that used lower doses in both arms is unclear. However,
it is possible that higher LAI doses were more effective
in showing superiority over OAPs, which may have been
dosed higher than necessary leading to dropout or nonadherence due to extrapyramidal side effects. However,
the interpretability of the results of potential dose differences is limited by missing information on mean doses
in the LAI and OAP arms, especially in old studies, and
by substantial differences in the suggested conversion factors from antipsychotic doses to CPZ equivalents, both of
which applied mostly to older studies using FGA-LAIs.
In contrast to our results, recent naturalistic studies
support the advantages of LAIs over OAPs in relapse
prevention30–32 as do mirror image studies.33,34 Tiihonen
et al.31 reported in a nationwide cohort that the risk of
rehospitalization with LAIs was one-third that of OAPs.
Most LAIs showed significant superiority compared
with each OAP counterpart regarding all-cause discontinuation. These results are especially important given
the potentially conservative bias in that the patients who
receive doctor’s choice LAIs are more likely to be nonadherent and more severely ill compared with patients
receiving doctor’s choice OAPs. Moreover, patients consenting to clinical trials of LAIs may not be representative of those prescribed LAIs in real-world settings.35
Participants in clinical trials might overrepresent patients
with better engagement with health care providers, better adherence to the treatment, lower illness severity,
and better cognitive capabilities to understand complex
issues. This difference in procedures can potentially lead
to a cohort bias in that less severely ill patients could be
enrolled in newer trials, particularly with increasing stringency of consent processes. This may explain the different results of older vs newer studies.
It is also important to recognize that participation in
a controlled trial alters the ecology of treatment delivery and experience. Patients in clinical trials are likely to
receive more and different types of attention than those
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in routine care, from measures of adherence to reminders
to attend clinical/research assessment sessions, or to the
provision of free medication.36 In addition, more frequent
monitoring during a trial enables psychiatrists to change
dosages according to the symptoms and provide supportive psychotherapy. It is difficult to determine what role
these factors might have in altering patterns of medication-taking in contrast to routine care and to what extent
they might, therefore, diminish the potential advantages
of LAIs in RCTs. The substantial disparity between the
large naturalistic cohort study results and those of RCTs
in this context would support such concerns.
To this point, we have assumed that LAIs must be more
effective than OAPs and have been trying to understand
why this is not apparent in the RCTs. We should also consider the possibility that if patients are fully adherent with
OAPs, the OAPs may actually be more efficacious than
LAIs as suggested by 2 recent trials.23,37,38 One interesting
hypothesis is the potential supersensitivity of the dopamine D2 receptor. Long-term, continuous D2 blockade
may increase the number and/or high-affinity state of
dopamine receptors.39,40 In addition, there are data suggesting that transient, rather than continuous blockade
of D2 receptors by “extended dosing” (eg, every other
day dosing), may be more efficacious in both animal and
human studies.41,42 Therefore, LAIs might result in more
continuous D2 blockade and receptor upregulation/
supersensitivity compared with OAPs. This effect would
be differentially stronger when the OAPs do not consist
of high-potency FGAs, as oral SGAs generally have less
complete or prolonged D2 blockade.
Regarding our study methodology, 2 points require
consideration. First, we utilized relapse rate preferentially based on survival analyses as a primary outcome.
We acknowledge that graphically calculated relapse rates
from survival curves can result in higher relapse rates compared with raw rates because the denominator decreases
as dropout occurs. On the other hand, raw relapse rates
do not count the potential relapse among patients who
dropped out. Moreover, in case of systematically different dropout rates between the treatment arms resulting in
shorter follow-up periods in one treatment compared with
another, a bias is introduced that disfavors the treatment
with better acceptability and greater persistence, as more
time is available for relapses to occur. For these reasons,
we believe that estimated rates may yield more accurate
data than raw relapse rates. However, we acknowledge the
problem of using estimations, rather than observed data,
and the mixing of estimated and raw rates from studies
not providing survival curves. To deal with this problem,
we analyzed the data in several ways, utilizing raw instead
of estimated relapse rates, and using raw or estimated
rates exclusively. The results remained the same, independent of how relapse rates were calculated.
Second, we used each the safety/efficacy and randomized population as denominators for the analyses.
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While ITT analysis is the gold standard for clinical trials, ITT definitions varied, which is problematic. Some
defined ITT as patients taking the medication at least
once, or receiving at least one assessment (modified
ITT), while others utilized the randomized population.
Moreover, several studies provided survival curves and
other results, which were solely based on the modified
ITT sample, and 1 study26 only presented the modified
ITT population. It is widely accepted that the reluctance toward injections is an important obstacle for
introducing LAIs.9 Some studies included in our analyses reported that patients dropped out when learning
of their LAI allocation. We considered it important
to include those patients as dropouts. However, given
the fact that more studies provided data using modified
ITT populations, we wanted to also examine the risk of
relapse once patients are on LAIs. Therefore, we analyzed the results in both populations separately, which
we considered the most conservative strategy, and there
were no important differences.
Results of these analyses have to be interpreted in the
context of several limitations. First, the database, though
larger than in the previous meta-analysis, is still limited.
For example, no long-term RCTs comparing paliperidone-LAI or aripiprazole-LAI with OAPs were available.
Furthermore, relapse definitions varied. We utilized each
study-defined relapse measure, and if no definition was
available, we used the most-appropriate relapse-related
outcome, ie, predominantly psychiatric hospitalization. The problem of heterogeneously defined relapse is
not surprising because there is no universally accepted
definition. On the other hand, this heterogeneity and
broad-based definition could also serve to enhance the
generalizability of the results. There was a 14-year gap
between the last study published in 1991 and the next
study published in 2005, which enabled us to examine
the effect of time when the study was conducted. Because
clinical and diagnostic concepts of the disease and therapeutic environments have changed over time, it is unclear,
which factors in addition to the almost exclusive study
of FGA-LAIs earlier and of SGA-LAIs later may have
influenced the results. In addition, heterogeneity of the
results was seen. Although the majority of studies targeted chronic patients with over 10 years of illness, some
targeted patients with even longer illness duration,12 while
some targeted relatively early-onset patients.43,44 One study
included patients with aggressive behavior,24 another
included patients who were hospitalized throughout the
study.23 Such clinical characteristics and different treatment settings may have caused heterogeneity. Of note,
risperidone-LAI studies were found to be most heterogeneous (τ2 = 0.09, I2 = 74%, Q = 30.92, df = 8, P = .0001).
Moreover, the reporting of drop out due to “adverse
events” is not always unambiguously restricted to physiologic/physical adverse effects. Rather, at times, discontinuation due to potential inefficacy-related outcomes,
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eg, anxiety, agitation, and worsening of psychosis, may
be counted as a side effect-related discontinuation, which
complicates the interpretation of this outcome.
Further limitations regarding the design of the analyzed studies include issues like treatment concealment
(7/21 were open studies), in- vs outpatient status (6/21
included inpatients throughout the study, or presumably
a significant portion of the study), study duration (6/21
were <1 year), and medication allocation (10/21 used different medications in the LAI and OAP arms). We consider the double-blind, double-dummy design favorable,
as it reduces expectancy and rater biases. At the same time,
however, this design itself is very different from clinical
practice, and might have contributed to increased selection bias. Moreover, inpatient studies apparently ensured
adherence, which may have strengthened the efficacy of the
OAP arm. Because nonadherence can increase over time,
one may expect also that the relative superiority of LAI
compared with OAPs develops over time. Such an effect
may explain the lower risk ratio in the longer term studies
when we analyzed separately results from studies lasting
<1 year (RR = 1.14, 95% CI: 0.82–1.58, P = .43) and those
lasting ≥1 year (RR = 0.91, 95% CI: 0.77–1.07, P = .25).
However, LAIs were not superior to OAPs in either
study subgroup, and some recent studies with durations
of ≥2 years12,14,15 also failed to show superiority of LAIs.
This calls into question that the study duration is a major
determinant. Using different medications in the oral and
LAI arms makes it difficult to disentangle the independent
efficacy of the delivery method from potential differences
in the efficacy of the 2 drugs including inappropriate dose
equivalency. We attempted to examine these issues by subgroup analyses, which all yielded the same result of similar
outcomes in the LAI and OAP groups.
In conclusion, while we had anticipated that LAIs
(with their intrinsically better adherence) would be more
effective than OAPs in preventing relapse, this was not
evident in a synthesis of the available RCTs. Notably,
these results are in contrast to naturalistic cohort studies showing superiority of LAIs in preventing rehospitalization. Further consideration is required to understand
the reasons for this discrepancy. In order to evaluate the
real-world effectivenss of LAIs compared with OAPs,
large and long pragmatic trials are needed, which better
resemble common clinical practice.
In our analysis, FGA-LAIs, but not SGA-LAIs, outperformed OAPs. The difference in effect was not statistically
significant and in any event could be due to a cohort effect.
The only way to determine if the FGA/SGA distinction is
important here would be to conduct head-to-head trials
of FGA-LAIs vs SGA-LAIs. It is likely that some studies
included in this analysis systematically excluded patients
who were expected to have poor adherence. If this is true,
then the results should not be generalized to these patients
and do not refute the possibility that LAIs may be superior to OAPs in this important group.
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